Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma.
Endometrial carcinoma
Estrogen
Hormone replacement therapy
Hormone therapy
Overall survival
Progesterone
Prognosis
Risk factors
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
01
09
2019
accepted:
07
12
2019
pubmed:
21
12
2019
medline:
21
7
2020
entrez:
21
12
2019
Statut:
ppublish
Résumé
Postmenopausal hormone therapy (HT) is known to affect the development of hormone-dependent endometrial carcinoma (type I EC). Several studies on breast and ovarian carcinoma have shown that HT influences the molecular profile and prognostic behavior of these tumors. This study aimed to investigate the influence of prior HT and other risk factors on the prognosis in a cohort of patients with invasive endometrial carcinoma (EC). Among 525 patients diagnosed with EC between 1987 and 2010, 426 postmenopausal patients were identified. Information regarding HT was available in 287 of these patients, 78 of whom had a history of HT and 209 of whom did not. Both overall survival (OS) and progression-free survival (PFS) were analyzed. In addition to OS and PFS, risk factors such as age at diagnosis, postmenopausal HT, body mass index (BMI), diabetes mellitus, tumor stage, EC type (I or II), and recurrences were analyzed. Relative to HT alone, women with EC and a history of HT had a longer survival than those with no HT. However, the Cox proportional hazards model showed that it was not HT itself, but rather other characteristics in the HT group that were causally associated with longer survival. Age (the older, the worse) and tumor stage (the higher, the worse) were significant influences on overall survival. Patients with HT also had lower BMIs, less diabetes, more type I EC, and fewer recurrences in comparison with the non-HT group. With regard to the PFS, it made no difference whether the patient was receiving HT.
Identifiants
pubmed: 31858234
doi: 10.1007/s00404-019-05414-3
pii: 10.1007/s00404-019-05414-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
289-294Références
Yu X, Zhou S, Wang J et al (2017) Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies. Breast Cancer 24:643–657
pubmed: 28601917
Sjogren LL, Morch LS, Lokkegaard E (2016) Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas 91:25–35
pubmed: 27451318
Ethier JL, Desautels DN, Amir E et al (2017) Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol. https://doi.org/10.1016/j.ygyno.2017.07.002
doi: 10.1016/j.ygyno.2017.07.002
pubmed: 28689667
Gemignani ML, Hetzel DJ (2017) Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer. Gynecol Oncol. https://doi.org/10.1016/j.ygyno.2017.06.023
doi: 10.1016/j.ygyno.2017.06.023
pubmed: 28662774
pmcid: 5639942
Lux MP, Janni W, Hartkopf AD et al (2017) Update breast cancer 2017 implementation of novel therapies. Geburtshilfe Frauenheilkd 77:1281–1290
pubmed: 29269955
pmcid: 5734938
Schneeweiss A, Lux MP, Janni W et al (2018) Update breast cancer 2018 (part 2) advanced breast cancer, quality of life and prevention. Geburtshilfe Frauenheilkd 78:246–259
pubmed: 29576630
pmcid: 5862553
Taran FA, Schneeweiss A, Lux MP et al (2018) Update breast cancer 2018 (part 1) primary breast cancer and biomarkers. Geburtshilfe Frauenheilkd 78:237–245
pubmed: 29576629
pmcid: 5862549
Untch M, Huober J, Jackisch C et al (2017) Initial treatment of patients with primary breast cancer: evidence, controversies, consensus: spectrum of opinion of German Specialists at the 15th International St Gallen Breast Cancer Conference (Vienna 2017). Geburtshilfe Frauenheilkd 77:633–644
pubmed: 28769126
pmcid: 5489401
Rauh C, Gass P, Heusinger K et al (2015) Association of molecular subtypes with breast cancer risk factors: a case-only analysis. Eur J Cancer Prev 24:484–490
pubmed: 25494290
Zhang Y, Zhao D, Gong C et al (2015) Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World J Surg Oncol 13:208
pubmed: 26108802
pmcid: 4511445
Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10–17
pubmed: 6822361
pmcid: 6822361
Wise MR, Jordan V, Lagas A et al (2016) Obesity and endometrial hyperplasia and cancer in premenopausal women: a systematic review. Am J Obstet Gynecol 214:689
pubmed: 26829507
Shaw E, Farris M, McNeil J et al (2016) Obesity and Endometrial Cancer. Recent results in cancer research. Fortschritte der Krebsforschung Progres dans les recherches sur le Cancer 208:107–136
pubmed: 27909905
Painter JN, O’Mara TA, Marquart L et al (2016) genetic risk score mendelian randomization shows that obesity measured as body mass index, but not waist: hip ratio, is causal for endometrial cancer. Cancer Epidemiol Biomarkers Prev 25:1503–1510
pubmed: 27550749
pmcid: 5093082
Meireles CG, Pereira SA, Valadares LP et al (2017) Effects of metformin on endometrial cancer: systematic review and meta-analysis. Gynecol Oncol. https://doi.org/10.1016/j.ygyno.2017.07.120
doi: 10.1016/j.ygyno.2017.07.120
pubmed: 28760367
Harris HR, Terry KL (2016) Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract 2:14
pubmed: 28620541
pmcid: 5424400
Burghaus S, Haberle L, Schrauder MG et al (2015) Endometriosis as a risk factor for ovarian or endometrial cancer results of a hospital-based case-control study. BMC Cancer 15:751
pubmed: 26487094
pmcid: 4618513
Liu J, Jiang W, Mao K et al (2015) Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Res Treat 150:439–445
pubmed: 25764167
pmcid: 4695996
Gusberg SB, Kardon P (1971) Proliferative endometrial response to theca-granulosa cell tumors. Am J Obstet Gynecol 111:633–643
pubmed: 4329746
Ziel HK, Finkle WD (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293:1167–1170
pubmed: 171569
Smith DC, Prentice R, Thompson DJ et al (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293:1164–1167
pubmed: 1186789
Beral V, Bull D, Reeves G et al (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365:1543–1551
pubmed: 15866308
Boardman HM, Hartley L, Eisinga A et al (2015) Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002229.pub4:CD002229
doi: 10.1002/14651858.CD002229.pub4:CD002229
pubmed: 25754617
Painter JN, O’Mara TA, Morris AP et al (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978–1987
pubmed: 29608257
pmcid: 5943470
O’Mara TA, Glubb DM, Amant F et al (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
pubmed: 30093612
pmcid: 6085317
Painter JN, O’Mara TA, Batra J et al (2015) Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Hum Mol Genet 24:1478–1492
pubmed: 25378557
Delahanty RJ, Xiang YB, Spurdle A et al (2013) Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 22:216–223
pubmed: 23221126
Long J, Zheng W, Xiang YB et al (2012) Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiol Biomarkers Prev 21:980–987
pubmed: 22426144
pmcid: 3372671
Spurdle AB, Thompson DJ, Ahmed S et al (2011) Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet 43:451–454
pubmed: 21499250
pmcid: 3770523
Cheng TH, Thompson DJ, O’Mara TA et al (2016) Five endometrial cancer risk loci identified through genome-wide association analysis. Nat Genet 48:667–674
pubmed: 27135401
pmcid: 4907351
Thompson DJ, O’Mara TA, Glubb DM et al (2016) CYP19A1 fine-mapping and mendelian randomization: estradiol is causal for endometrial cancer. Endocr Relat Cancer 23:77–91
pubmed: 26574572
pmcid: 4697192
O’Mara TA, Glubb DM, Painter JN et al (2015) Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocr Relat Cancer 22:851–861
pubmed: 26330482
pmcid: 4559752
Lobo RA (2017) Hormone-replacement therapy: current thinking. Nat Rev Endocrinol 13:220–231
pubmed: 27716751
Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333
Katalinic A, Stegmaier C, Rawal R et al (2007) Less hormone replacement therapy, less breast cancer in Germany? Geburtshilfe Frauenheilkd 67:1217–1221
Schwabe U, Paffrath D, Ludwig WD (2017) Arzneiverordnungs-report 2017. Springer, Berlin
Hodis HN, Mack WJ (2014) Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. J Steroid Biochem Mol Biol 142:68–75
pubmed: 23851166
Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310:1353–1368
pubmed: 24084921
Chlebowski RT, Anderson GL, Sarto GE et al (2016) Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women’s Health Initiative Randomized Trial. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv350
doi: 10.1093/jnci/djv350
pubmed: 28003316
pmcid: 5174188
Beckmann MW, Gitsch G, Emons G et al (2006) The newly established subspecialty gynecological oncology a national and an international chance? Geburtshilfe Frauenheilkd 66:4
Binder PS, Mutch DG (2014) Update on prognostic markers for endometrial cancer. Womens Health (London) 10:277–288
Ko EM, Walter P, Clark L et al (2014) The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance. Gynecol Oncol 133:28–32
pubmed: 24680588
Secord AA, Hasselblad V, Von Gruenigen VE et al (2016) Body mass index and mortality in endometrial cancer: a systematic review and meta-analysis. Gynecol Oncol 140:184–190
pubmed: 26524722
Marshall SF, Clarke CA, Deapen D et al (2010) Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res 12:R4
pubmed: 20064209
pmcid: 2880422
Rauh C, Schuetz F, Rack B et al (2015) Hormone therapy and its effect on the prognosis in breast cancer patients. Geburtshilfe Frauenheilkd 75:588–596
pubmed: 26166840
pmcid: 4490917
Schuetz F, Diel IJ, Pueschel M et al (2007) Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 196(342):e341–349
Collaborative Group on Epidemiological Studies of Ovarian C, Beral V, Gaitskell K et al (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835–1842
Pearce CL, Chung K, Pike MC et al (2009) Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 115:531–539
pubmed: 19127543
pmcid: 4203480
Hein A, Thiel FC, Bayer CM et al (2013) Hormone replacement therapy and prognosis in ovarian cancer patients. Eur J Cancer Prev 22:52–58
pubmed: 22694828